Peer-Reviewed Journal Articles

Published in Internationally Recognized Peer-Reviewed Journals

Lupus Precision Medicine Products (setting the stage for LuGENE®)

Clinical management of Lupus in the US: a claims-based analysis
Lupus Sci. Med. 11: 1136, 2023.

Addressing Lupus Pillars for Health Advancement (ALPHA) Project: Lupus Clinical Trial Outcome measures and the patient perspective
Lupus Sci. Med. 10: e000901, 2023.

Recent advances in the use of machine learning and artificial intelligence to improve diagnosis, predict flares and enrich trials in lupus
Curr Opin Rheum 32, 2022.

Diagnosis of Systemic Lupus Erythematosus in the Age of Precision Medicine
Diagnoses Without Names, pp. 77-87, 2022.

Increasing ancestral diversity in SLE Clinical Studies ArthritisCare & Research 74: 420-426.

Current Status of the Evaluation and Management of Lupus Patients and Future Prospects
Frontiers in Medicine 8:682544, 2021.

Role of ANA testing in the classification of patients with SLE.
Ann. Rheum. Dis 80:e124, 2021.

New insights into the role of antinuclear antibodies in SLE.
Nat. Rev. Rheumatol. 16:565, 2020.

Current challenges in the development of new treatments for lupus
Ann.Rheum.Dis. 78:729, 2019.

Biomarkers as entry criteria for clinical trials of new therapies for systemic lupus erythematosus
Arthritis and Rheumatism 69:487, 2017.

Are Autoantibodies the Targets of B Cell Directed Therapy?
Nature Reviews Rheumatology 7: 1610, 2013.

Medical Affairs for LuGENE-Dx®

Increasing Ancestral Diversity in Systemic Lupus Erythematosus Clinical Studies
Arthritis Care Res. 74:420, 2022.
doi: 10.1002/acr.24474.

Deconvoluting the heterogeneity of SLE: the contribution of ancestry
Journal of Allergy and Clinical Immunology, 2021

Patient  ancestry significantly contributes to molecular heterogeneity of Systemic Lupus Erythematosus
JCI Insights 5(15) e140380, 2020

Engaging African ancestry participants in SLE clinical trials
Lupus Sci. Med. 5:e000297, 2018
doi: 10.1136/lupus-2018-000297.

Pin It on Pinterest